ClinicalTrials.gg
CompletedNCT02696915Updated Mar 8, 2016

Fascia Iliaca Compartment Block for Proximal-end Femur Fractures

An interventional study of Placebo and Bupivacaine in Proximal Femur Fractures, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-03-08.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Fracture femur is a common injury which is associated with excruciating pain. Positioning for neuraxial blocks is always challenging because even slight overriding of the fracture ends is intensely painful .It can causing major patient distress which accompanied by well-known physiological sequelae such as sympathetic activation causing tachycardia, hypotension, and increased cardiac work that may compromise high-risk cardiac patients.

Fascia iliaca compartment block is highly effective in blocking lateral cutaneous nerve of the thigh and femoral nerve. Fascia iliaca compartment block is not only easy to perform but it is also associated with minimal risk as the local anesthetic is injected at a safe distance from the femoral artery and femoral nerve. It is always safe to perform the fascia iliaca compartment block prior to spinal anesthesia as the patient can respond during administration of the local anesthetic and can prevent intra-neuronal injections

Read the detailed description

On arrival to the pre-operative holding area half hour before the scheduled surgery. Patient will be connected to basal monitoring devices; pulse oximetry and non- invasive blood pressure. Fascia iliaca compartment block will be performed with the aid of ultrasound device in all cases.The injected local anesthetic solution will be prepared by a staff member who was not involved in the study) according to the randomization. After 20 minutes from the injection the investigators will assessed nerves that had been blocked.

On arrival to the operative theater, under complete aseptic technique spinal anesthesia will be carried out in the sitting position (if there is severe pain at positioning we will use lateral position) at space between L3-4 or L4-5 using a 25-gauge spinal quincke needle. After feeling the desired space, the needle will be advanced (paramedian approach) till free flow of cerebrospinal fluid dropped from the needle then 15 mg hyperbaric bupivacaine+20mic fentanyl will be injected.

02

Conditions studied

  • Proximal Femur Fractures
03

In context

Lead sponsor

Mansoura University is the lead sponsor of 1,114 studies on the registry; 184 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • American Society of Anesthesiologist physical status I to III
  • Patients scheduled for fixation for proximal end femur fracture

Exclusion criteria

Exclusion Criteria:

  • Patients refusal
  • Morbid obese patients (BMI>40)
  • Bleeding diathesis
  • Previous femoral bypass surgery
  • Inguinal hernia
  • Inflammation/infection over injection site
  • Peripheral neuropathy
  • Allergy to local anesthetics agents used.
  • Severely altered consciousness level
  • Psychiatric disorders
  • Polytrauma
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Patients received ultrasound guided fascia iliaca compartment block using 40 ml of saline 0.9%. Then intrathecal medications will be administered.

    Drug: Placebo · Device: Ultrasound guided fascia iliaca compartment block · Drug: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)

  • Active comparator
    Bupivacaine

    Patients received ultrasound guided fascia iliaca compartment block using 40 ml of 0.25% bupivacaine. Then intrathecal medications will be administered.

    Drug: Bupivacaine · Device: Ultrasound guided fascia iliaca compartment block · Drug: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)

Interventions

  • DrugPlacebo

    Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml

  • Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml

  • DeviceUltrasound guided fascia iliaca compartment block

    Ultrasound guided fascia iliaca compartment block

  • DrugIntrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)

    Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms

06

What researchers measure

Primary outcomes

  1. Pain scores

    Pain was assessed using visual analogue score

    Time frame: For 24 hours after performance the blockade

Secondary outcomes

  1. Heart rate

    Time frame: For 24 hours after performance the blockade

  2. Blood pressure

    Time frame: For 24 hours after performance the blockade

  3. Peripheral oxygen saturation

    Time frame: For 24 hours after performance the blockade

  4. Time to performing spinal anesthesia

    Time from the placement of patient in the optimum position to the intra-thecal injection of bupivacaine

    Time frame: For 30 min after placement of patient in the optimum position

  5. Number of trials of dural puncture

    Time frame: For 30 min after placement of patient in the optimum position

  6. Duration of motor blockade

    Time frame: For 12 hours after performing spinal anesthesia

  7. Duration of sensory blockade

    Time frame: For 12 hours after performing spinal anesthesia

  8. Duration of analgesia

    Time from performing spinal anesthesia to first analgesic request

    Time frame: For 24 hours after performing spinal anesthesia

  9. Cumulative consumption of analgesics

    Total opioid or other analgesics received for the first 24 hours after surgery.

    Time frame: For 24 hours after performing spinal anesthesia

07

Study locations

1 site
  • Mansoura University Hospitals
    Al Mansurah, DK 050, Egypt
08

References and documents

Publications

  • Guay J, Kopp S. Peripheral nerve blocks for hip fractures in adults. Cochrane Database Syst Rev. 2020 Nov 25;11(11):CD001159. doi: 10.1002/14651858.CD001159.pub3. PubMed 33238043 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jul 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2016
First posted
Mar 2, 2016
Start
Jan 2015
Primary completionActual
Jul 2015
CompletionActual
Aug 2015
Last update
Mar 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02696915
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
Jan 2015
Primary completion
Jul 2015
Completion
Aug 2015
Last update
Mar 8, 2016

Study contacts

Reem A El Sharkawy, MD
study chair · Lecturer of Anesthesia and Surgical Intensive Care

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion